BRCA1 and neoplasm: Two-thirds of initial IDHWT tumours (63%; 24/38) harboured potentially actionable variation most frequently in PTEN (29%; 11/38), followed by BRCA1 (18%; 7/38), BRCA2 (18%; 7/38), TP53 (18%; 7/38), EGFR (16%; 6/38), ATM (16%; 6/38), and ATR (8%; 3/38; see Table 4).